Experimental radioactive drug enters human testing for Tough-to-Treat cancers
NCT ID NCT07274852
Summary
This early-stage study is testing a new radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head/neck, and other solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose, see how the body processes the drug, and check for early signs that it might help control cancer. The study will enroll about 22 adults whose cancer has spread or cannot be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.